Genetics of PTEN Hamartoma Tumour Syndrome

Abstract

The PTEN hamartoma tumour syndrome (PHTS) represents a group of clinically related syndromes caused by germline mutations in the PTEN gene. These include Cowden syndrome (CS), Bannayan–Riley–Ruvalcaba syndrome, adult Lhermitte–Duclos disease and autism spectrum disorders with macrocephaly. PTEN mutations lead to increased cancer risks (including breast, thyroid, uterine, renal cell and colon cancers) and benign overgrowth of multiple tissues, presenting in part as dermatologic lesions, gastrointestinal polyps, thyroid structural lesions, lipomas and vascular lesions. Historically, data on the clinical features of PHTS have been based primarily on collected case reports from the literature. More recently, findings from several large United States and European cohorts have added greatly to our understanding of PHTS. The bulk of these data are on patients with CS, the most common of the PHTS component syndromes. Testing and management criteria and recently revised clinical diagnostic criteria have been established for PHTS.

Key Concepts:

  • PHTS is an important group of clinical disorders, including Cowden syndrome and Bannayan–Riley–Ruvalcaba syndrome, which are defined by presence of a mutation in the PTEN gene.

  • These conditions are of relevance to many clinical specialties because of significantly increased risks for benign and malignant tissue overgrowth.

  • The data that are available on risks for malignancy and other features of the syndrome have been almost entirely obtained on cohorts of patients who presented to medical attention and were tested because they demonstrated a significant number of PHTS features. This inherently should lead to overestimates of the prevalence of these features.

  • Projected lifetime cancer risks in recent studies have been approximately 77–85% for breast cancer (women only), 20–38% for thyroid cancer, 20–30% for uterine cancer, 15–34% for renal cell carcinoma and 9–16% for colon cancer.

  • Common nonmalignant features include gastrointestinal polyps, macrocephaly, specific skin lesions and structural thyroid lesions. Less common features include Lhermitte–Duclos disease, autism spectrum disorder, mental retardation/developmental delay, testicular lipomatosis and vascular anomalies.

  • Criteria for making a clinical diagnosis of this syndrome have been recently updated to reflect current literature.

  • The US National Comprehensive Cancer Network has developed testing criteria and medical management criteria which are updated annually.

Keywords: PTEN; PTEN hamartoma tumour syndrome; Cowden syndrome; Bannayan–Riley–Ruvalcaba syndrome

References

Bayley JP (2011) Succinate dehydrogenase gene variants and their role in Cowden syndrome. American Journal of Human Genetics 88(5): 674–675.

Bennett KL, Mester J and Eng C (2011) Germline epigenetic regulation of KILLIN in Cowden and Cowden‐like syndrome. Journal of the American Medical Association 304(24): 2724–2731.

Bubien V, Bonnet F, Brouste V et al. (2013) High cumulative risks of cancer in patients with PTEN hamartoma tumour syndrome. Journal of Medical Genetics 50(4): 255–263.

Butler MG, Dasouki MJ, Zhou XP et al. (2005) Subset of individuals with autism spectrum disorders and extreme macrocephaly associated with germline PTEN tumour suppressor gene mutations. Journal of Medical Genetics 42(4): 318–321.

Chibon F, Primois C, Bressieux JM et al. (2008) Contribution of PTEN large rearrangements in Cowden disease: a multiplex amplifiable probe hybridisation (MAPH) screening approach. Journal of Medical Genetics 45(10): 657–665.

Cohen MM Jr, Turner JT and Biesecker LB (2003) Proteus syndrome: misdiagnosis with PTEN mutations. American Journal of Medical Genetics Part A 122A(4): 323–324.

Eng C (1997) Cowden syndrome. Journal of Genetic Counseling 6: 181–191.

Eng C (2000) Will the real Cowden syndrome please stand up: revised diagnostic criteria. Journal of Medical Genetics 37 (11): 828–830.

Gorlin RJ, CohenMM Jr, Condon LM and Burke BA (1992) Bannayan‐Riley‐Ruvalcaba syndrome. American Journal of Medical Genetics 44(3): 307–314.

Hanssen AMN and Fryns JP (1995) Cowden syndrome. Journal of Medical Genetics 32: 117–119.

Heald B, Mester J, Rybicki L et al. (2010) Frequent gastrointestinal polyps and colorectal adenocarcinomas in a prospective series of PTEN mutation carriers. Gastroenterology 139(6): 1927–1933.

Hendriks YM, Verhallen JT, van der Smagt JJ et al. (2003) Bannayan‐Riley‐Ruvalcaba syndrome: further delineation of the phenotype and management of PTEN mutation‐positive cases. Familial Cancer 2(2): 79–85.

Hopkins BD, Hodakoski C, Barrows D, Mense SM and Parsons RE (2014) PTEN function: the long and the short of it. Trends in Biochemical Sciences 39(4): 183–190.

Iacobas I, Burrows PE, Adams DM et al. (2011) Oral rapamycin in the treatment of patients with hamartoma syndromes and PTEN mutation. Pediatric Blood and Cancer 57(2): 321–323.

Liaw D, Marsh DJ, Li J et al. (1997) Germline mutations of the PTEN gene in Cowden disease, an inherited breast and thyroid cancer syndrome. Nature Genetics 16(1): 64–67.

Marsh DJ, Coulon V, Lunetta KL et al. (1998) Mutation spectrum and genotype‐phenotype analyses in Cowden disease and Bannayan‐Zonana syndrome, two hamartoma syndromes with germline PTEN mutation. Human Molecular Genetics 7(3): 507–515.

Marsh DJ, Kum JB, Lunetta KL et al. (1999) PTEN mutation spectrum and genotype‐phenotype correlations in Bannayan‐Riley‐Ruvalcaba syndrome suggest a single entity with Cowden syndrome. Human Molecular Genetics 8(8): 1461–1472.

McBride KL, Varga EA, Pastore MT et al. (2010) Confirmation study of PTEN mutations among individuals with autism or developmental delays/mental retardation and macrocephaly. Autism Research 3(3): 137–141.

Mester J and Eng C (2012) Estimate of de novo mutation frequency in probands with PTEN hamartoma tumor syndrome. Genetics in Medicine 14(9): 819–822.

Mester JL, Tilot AK, Rybicki LA, Frazier TW and Eng C (2011) Analysis of prevalence and degree of macrocephaly in patients with germline PTEN mutations and of brain weight in PTEN knock‐in murine model. European Journal of Human Genetics 19(7): 763–768.

National Comprehensive Cancer Network, I. (2014) The NCCN Guidelines Genetic/Familial High‐Risk Assessment: Breast and Ovarian (Version 1.2014). Available at: www.nccn.org (accessed on 09 April 2014).

Nelen MR, Kremer H, Konings IBM et al. (1999) Novel PTEN mutations in patients with Cowden disease: absence of clear genotype‐phenotype correlations. European Journal of Human Genetics 7(3): 267–273.

Nelen MR, Padberg GW, Peeters EAJ et al. (1996) Localization of the gene for Cowden disease to 10q22‐23. Nature Genetics 13(1): 114–116.

Nelen MR, van Staveren CG, Peeters EAJ et al. (1997) Germline mutations in the PTEN/MMAC1 gene in patients with Cowden disease. Human Molecular Genetics 6(8): 1383–1387.

Ni Y, He X, Chen J et al. (2012) Germline SDHx variants modify breast and thyroid cancer risks in Cowden and Cowden‐like syndrome via FAD/NAD‐dependant destabilization of p53. Human Molecular Genetics 21(2): 300–310.

Ni Y, Zbuk KM, Sadler T et al. (2008) Germline mutations and variants in the succinate dehydrogenase genes in Cowden and Cowden‐like syndromes. American Journal of Human Genetics 83(2): 261–268.

Nieuwenhuis MH, Kets CM, Murphy‐Ryan M et al. (2014) Cancer risk and genotype‐phenotype correlations in PTEN hamartoma tumor syndrome. Familial Cancer 13(1): 57–63.

Orloff MS, He X, Peterson C et al. (2013) Germline PIK3CA and AKT1 mutations in Cowden and Cowden‐like syndromes. American Journal of Human Genetics 92(1): 76–80.

Parisi M, Dinulos MB, Leppid KA et al. (2001) The spectrum and evolution of phenotypic findings in PTEN mutation positive cases of Bannayan‐Riley‐Ruvalcaba syndrome. Journal of Medical Genetics 38(1): 52–57.

Pilarski R (2009) Cowden syndrome: a critical review of the clinical literature. Journal of Genetic Counseling 18(1): 13–27.

Pilarski R, Burt R, Kohlman W et al. (2013) Cowden syndrome and the PTEN hamartoma tumor syndrome: systematic review and revised diagnostic criteria. Journal of the National Cancer Institute 105(21): 1607–1616.

Pilarski R and Eng C (2004) Will the real Cowden syndrome please stand up (again)? Expanding mutational and clinical spectra of the PTEN hamartoma tumour syndrome. Journal of Medical Genetics 41(5): 323–326.

Pilarski R, Stephens JA, Noss R, Fisher JL and Prior TW (2011) Predicting PTEN mutations: an evaluation of Cowden syndrome and Bannayan‐Riley‐Ruvalcaba syndrome clinical features. Journal of Medical Genetics 48(8): 505–512.

Riegert‐Johnson DL, Gleeson FC, Roberts M et al. (2010) Cancer and Lhermitte‐Duclos disease are common in Cowden syndrome patients. Hereditary Cancer in Clinical Practice 8(1): 6.

Salem OS and Steck WD (1983) Cowden's disease (multiple hamartoma and neoplasia syndrome). A case report and review of the English literature. Journal of the American Academy of Dermatology 8(5): 686–696.

Schmid GL, Kassner F, Uhlig HH et al. (2014) Sirolimus treatment of severe PTEN hamartoma tumor syndrome: case report and in vitro studies. Pediatriac Research 75(4): 527–534.

Starink TM (1984) Cowden's disease: analysis of fourteen new cases. Journal of the American Academy of Dermatology 11(6): 1127–1141.

Tan MH, Mester J, Peterson C et al. (2011) A clinical scoring system for selection of patients for PTEN mutation testing is proposed on the basis of a prospective study of 3042 probands. American Journal of Human Genetics 88(1): 42–56.

Tan MH, Mester JL, Ngeow J et al. (2012) Lifetime cancer risks in individuals with germline PTEN mutations. Clinical Cancer Research 18(2): 400–407.

Tan TC and Ho LC (2007) Lhermitte‐Duclos disease associated with Cowden syndrome. Journal of Clinical Neuroscience 14(8): 801–805.

Thompson ER, Gorringe KL, Choong DY et al. (2012) Analysis of KLLN as a high‐penetrance breast cancer predisposition gene. Breast Cancer Research and Treatment 134(2): 543–547.

Tsou HC, Teng DH, Ping XL et al. (1997) The role of MMAC1 mutations in early‐onset breast cancer: causative in association with Cowden syndrome and excluded in BRCA1‐negative cases. American Journal of Human Genetics 61(5): 1036–1043.

Varga EA, Pastore M, Prior T, Herman GE and McBride KL (2009) The prevalence of PTEN mutations in a clinical pediatric cohort with autism spectrum disorders, developmental delay, and macrocephaly. Genetics in Medicine 11(2): 111–117.

Zhou X, Hampel H, Thiele H et al. (2001) Association of germline mutation in the PTEN tumour suppressor gene and Proteus and Proteus‐like syndromes. Lancet 358(9277): 210–211.

Zhou XP, Marsh DJ, Hampel H et al. (2000) Germline and germline mosaic mutations associated with a Proteus‐like syndrome of hemihypertrophy, lower limb asymmetry, arterio‐venous malformations and lipomatosis. Human Molecular Genetics 9: 765–768.

Zhou XP, Marsh DJ, Morrison CD et al. (2003) Germline inactivation of PTEN and dysregulation of the phosphoinositol‐3‐kinase/Akt pathway cause human Lhermitte‐Duclos disease in adults. American Journal of Human Genetics 73(5): 1191–1198.

Zhou XP, Waite KA, Pilarski R et al. (2003) Germline PTEN promoter mutations and deletions in Cowden/Bannayan‐Riley‐Ruvalcaba syndrome result in aberrant PTEN protein and dysregulation of the phosphoinositol‐3‐kinase/AKT pathway. American Journal of Human Genetics 73(2): 404–411.

Zhou XP, Woodford‐Richens K, Lehtonen R et al. (2001) Germline mutations in BMPR1A/ALK3 cause a subset of cases of juvenile polyposis syndrome and of Cowden and Bannayan‐Riley‐Ruvalcaba syndromes. American Journal of Human Genetics 69(4): 704–711.

Further Reading

Hollander MC, Blumenthal GM and Dennis PA (2011) PTEN loss in the continuum of common cancers, rare syndromes and mouse models. Nature Reviews Cancer 11(4) :289–301.

Contact Editor close
Submit a note to the editor about this article by filling in the form below.

* Required Field

How to Cite close
Pilarski, Robert T(Jul 2014) Genetics of PTEN Hamartoma Tumour Syndrome. In: eLS. John Wiley & Sons Ltd, Chichester. http://www.els.net [doi: 10.1002/9780470015902.a0025733]